Search Results
Your search for ,sIX matches 2897 pages
Showing 551 - 600Recurrence-Free Survival as Surrogate for Overall Survival in Patients Undergoing Resection of Colorectal Liver Metastases
In a single-center retrospective study and a separate meta-analysis reported in The Lancet Oncology, Ecker et al found low correlations between recurrence-free survival and overall survival among patients undergoing resection of colorectal cancer liver metastases. As stated by the investigators,...
Study Explores Link Between Use of Antipsychotic Agents and Increased Breast Cancer Risk
A research team from the Centre for Safe Medication Practice and Research (CSMPR) in the Department of Pharmacology and Pharmacy at the University of Hong Kong (HKUMed) conducted a systematic review and meta-analysis of observational studies with over 2 million individuals and estimated a moderate...
An Aggressive Type of Non-Hodgkin Lymphoma Threatened My Life
I was just 31 and about to give birth to my fourth child, Yitzchok, when I received a diagnosis of primary mediastinal large B-cell lymphoma. The news was terrifying and crippling. For months, I had been experiencing shortness of breath, coughing, and a pain in my left shoulder, all of which were...
Bispecific Antibodies and the Dawn of a New Era in Treatment of Multiple Myeloma
“I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning!” —Steve Jobs Relapsed and refractory multiple myeloma remains a treatment challenge. Promising responses have been demonstrated with bispecific antibodies, with a...
Sacituzumab Govitecan in Pretreated Patients With Hormone Receptor–Positive, HER2-Negative Endocrine-Resistant Advanced Breast Cancer
As reported in the Journal of Clinical Oncology by Hope S. Rugo, MD, FASCO, and colleagues, the phase III TROPiCS-02 trial has shown a significant progression-free survival benefit with sacituzumab govitecan-hziy vs chemotherapy in previously treated patients with hormone receptor (HR)-positive,...
Concurrent Chemoradiation Therapy With Weekly Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma
When combined with radiotherapy as definitive treatment of locally advanced head and neck squamous cell carcinoma, cisplatin at a dose of 40 mg/m2 weekly is noninferior to cisplatin at 100 mg/m2 every 3 weeks, according to the results of the ConCERT trial.1 These findings were presented by Atul...
Addition of Telaglenastat to Cabozantinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
As reported in JAMA Oncology by Nizar M. Tannir, MD, FACP, and colleagues, the phase II CANTATA trial showed no improvement in progression-free survival with the addition of the glutaminase inhibitor telaglenastat to cabozantinib in previously treated patients with metastatic clear cell renal cell...
Addition of Sintilimab and Bevacizumab Biosimilar to Chemotherapy for Patients With Advanced EGFR-Mutated NSCLC and Disease Progression on EGFR Inhibitors
In an interim analysis of the Chinese phase III ORIENT-31 trial reported in The Lancet Oncology, Lu et al found that the addition of sintilimab and the bevacizumab biosimilar IBI305 to chemotherapy prolonged progression-free survival in patients with advanced EGFR-mutated nonsquamous non–small cell ...
Is PD-L1 Expression a Good Predictor of Survival Benefit in Patients With Advanced Gastroesophageal Cancer Treated With Immunotherapy?
In a systematic review and meta-analysis of phase III trials of immune checkpoint inhibitor treatment in patients with advanced gastroesophageal cancer reported in JAMA Oncology, Harry H. Yoon, MD, MS, and colleagues found that PD-L1 expression was the strongest predictor of overall survival...
FDA Approves Durvalumab-Based Combination for Locally Advanced or Metastatic Biliary Tract Cancer
On September 2, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer. TOPAZ-1 Efficacy was evaluated in TOPAZ-1 (ClinicalTrials.gov identifier:...
Addition of Chemotherapy to Gefitinib in First-Line Treatment of Advanced NSCLC With EGFR Mutations
In an updated analysis of the Japanese phase III NEJ009 trial reported in the Journal of Clinical Oncology, Miyauchi et al found that gefitinib plus carboplatin/pemetrexed was associated with prolonged progression-free survival and progression-free survival 2—but loss of significance in overall...
Tislelizumab Plus Chemotherapy Improves Progression-Free Survival in Nasopharyngeal Cancer
The addition of the checkpoint inhibitor tislelizumab to first-line chemotherapy significantly reduced the risk of disease progression or death by 50% and, despite a 49% crossover rate, numerically boosted overall survival in patients with recurrent or metastatic nasopharyngeal cancer, Zhang et al...
Head and Neck Cancer 2021–2022 Almanac
Head and neck cancer is the seventh most common cancer in the world, with 1.1 million new diagnoses reported annually.1 In the United States, the incidence of oral and pharyngeal cancers is over 54,000 cases per year, resulting in over 11,000 yearly deaths.2 Although smoking and alcohol consumption ...
Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia
On May 20, 2022, azacitidine for injection was approved by the U.S. Food and Drug Administration for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.1 Supporting Efficacy Data Approval was based on findings in the multicenter AZA-JMML-001 trial (ClinicalTrials.gov...
Neoadjuvant Nivolumab Plus Ipilimumab in Localized dMMR/MSI-H Gastric Cancer
As reported in the Journal of Clinical Oncology by Thierry André, MD, and colleagues, the French (GERCOR) phase II NEONIPIGA trial has shown a high pathologic complete response rate with nivolumab/ipilimumab neoadjuvant therapy in patients with localized deficient mismatch repair...
Rituximab, Lenalidomide, and Ibrutinib With Sequential Addition of Chemotherapy in Newly Diagnosed DLBCL: Smart Start Trial
In a single-institution phase II trial (Smart Start) reported in the Journal of Clinical Oncology, Jason Westin, MD, MS, and colleagues found that initiating treatment with rituximab, lenalidomide, and ibrutinib (RLI) followed by the sequential addition of chemotherapy resulted in high response...
Durvalumab/Tremelimumab for Previously Treated Patients With Advanced Soft-Tissue and Bone Sarcomas
In a single-center phase II trial reported in The Lancet Oncology, Somaiah et al found that the combination of durvalumab and tremelimumab showed activity in a group of previously treated patients with advanced or metastatic soft-tissue and bone sarcomas of various subtypes. Study Details In the...
Cardiovascular Mortality and Cancer Mortality Over Time Among Cancer Survivors
In an English retrospective cohort study reported in JACC: Cardio-Oncology, Helen Strongman, PhD, of the Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, and colleagues found that cardiovascular mortality ultimately exceeded mortality from common...
Stem Cell Boost as Salvage Therapy for Severe Hematologic Toxicity After CD19 CAR T-Cell Therapy
In a retrospective study reported in a research letter in Blood Advances, Rejeski et al found that a stem cell boost was successful in treating severe hematologic toxicity in patients who had received CD19 chimeric antigen receptor (CAR) T-cell therapy for refractory B-cell malignancies. Study...
RATIONALE-306: Survival Benefit Attained With Tislelizumab in Advanced Esophageal Cancer
In patients with advanced or metastatic esophageal squamous cell carcinoma, the addition of the checkpoint inhibitor tislelizumab to first-line chemotherapy significantly improved overall survival vs chemotherapy alone, according to an interim analysis of the global phase III RATIONALE-306 trial....
Robert Uzzo, MD, MBA, FACS, Appointed President and CEO of Fox Chase Cancer Center
Robert Uzzo, MD, MBA, FACS, has been named President and Chief Executive Officer (CEO) of Fox Chase Cancer Center, Philadelphia. In addition, Dr. Uzzo will assume the roles of Executive Vice President, Cancer Services for Temple University Health System, and Senior Associate Dean, Clinical Cancer...
Long-Term Regional Disease Control With Sentinel Lymph Node Biopsy in Patients With Melanoma
In an analysis of the Multicenter Selective Lymphadenectomy Trial II reported in JAMA Surgery, Crystal et al found that patients with melanoma with sentinel lymph node (SLN) metastasis who were randomly assigned to observation vs completion lymph node dissection (CLND) following SLN biopsy...
ASCO Releases First Comprehensive Evidence-Based Guidelines for Metastatic Clear Cell Renal Cell Carcinoma
ASCO has released the first comprehensive set of guidelines for the management of metastatic clear cell renal cell carcinoma (RCC).1 The guidelines are subdivided into six main sections: diagnosis, the role of cytoreductive nephrectomy, first-line systemic treatment, second- or later-line systemic...
Expert Point of View: Rebecca A. Dent, MD
The invited discussant of the DS8201-A-U105 trial, Rebecca A. Dent, MD, Head of the Department of Medical Oncology, Senior Consultant, and Chief of the Breast Medical Oncology Service at the National Cancer Center Singapore, said the results were reassuring in terms of safety and may pave the way...
FDA Approves Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer
On August 5, 2022, the U.S. Food and Drug Administration approved darolutamide (Nubeqa) tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer. The evaluation of efficacy was based on ARASENS (ClinicalTrials.gov identifier NCT02799602), a...
MRD-Adapted Study of Elotuzumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Without Transplantation Intent
In a phase II trial reported in JAMA Oncology, Derman et al found that a measurable residual disease (MRD)-adapted strategy with elotuzumab (Elo) plus carfilzomib, lenalidomide, and dexamethasone (KRd) was associated with high rates of stringent complete response and MRD-negative status in patients ...
Outcomes With Postconsolidation Dinutuximab-Based Immunotherapy for Neuroblastoma
In an analysis reported in the Journal of Clinical Oncology, Desai et al described outcomes with postconsolidation dinutuximab-based immunotherapy for high-risk neuroblastoma in a cohort of patients from the Children’s Oncology Group ANBL0032 trial following cessation of randomized treatment. Study ...
Fewer People Tried to Quit Smoking During COVID-19 Pandemic, Study Shows
A new study led by researchers at the American Cancer Society (ACS), shows serious smoking cessation activity declined among adults in the United States immediately after the onset of the COVID-19 pandemic and persisted for more than a year. Declines in attempts to quit smoking were largest among...
Adhering to a Healthy Diet After a Head and Neck Cancer Diagnosis May Boost Survival
Patients with squamous cell carcinoma of the head or neck were 93% less likely to die of any cause during the first 3 years after diagnosis if they ate a healthy diet high in nutrients found to deter chronic disease, according to results published by Vieytes et al in Frontiers in Nutrition. The...
ATLAS Trial: Risk-Adapted Triplet Maintenance Therapy May Benefit Some Patients With Multiple Myeloma
For newly diagnosed patients with multiple myeloma participating in the international phase III ATLAS trial, use of carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after induction and autologous stem cell transplantation (ASCT) significantly reduced the risk of disease...
Maintenance Olaparib vs Placebo in Germline BRCA-Mutated Metastatic Pancreatic Cancer: Overall Survival Analysis of the POLO Trial
As reported in the Journal of Clinical Oncology by Hedy L. Kindler, MD, FASCO, and colleagues, the final overall survival analysis of the phase III POLO trial showed no significant difference between the maintenance olaparib group vs the placebo group in patients with germline BRCA-mutated...
ECHELON-1 Trial: Brentuximab Vedotin With Chemotherapy Offers Survival Benefit in Stage III or IV Hodgkin Lymphoma
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (a regimen known as A+AVD) significantly reduced the risk of mortality vs standard treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with previously untreated stage III or IV classical Hodgkin...
Hematology Highlights From ASCO 2022
A multitude of presentations were available to attendees at the 2022 ASCO Annual Meeting, including hundreds in the hematologic malignancies tracks. In addition to coverage in The ASCO Post of the major news stories at the meeting, here we offer summaries of additional studies of special interest...
Study Reports Time-Limited Venetoclax-Based Regimens of Benefit in Front-Line Treatment of CLL
Time-limited venetoclax-based regimens provide deeper and more durable remissions than chemoimmunotherapy combinations in patients with previously untreated chronic lymphocytic leukemia (CLL), regardless of patients’ fitness, according to late-breaking data presented during the European Hematology...
Adjuvant Everolimus Narrowly Misses Statistical Significance in RCC, Except for Very High–Risk Patients
In the phase III EVEREST trial, adjuvant everolimus improved median recurrence-free survival in patients with resected renal cell carcinoma (RCC), but this finding failed to be statistically significant in the total study population of 1,499 patients, according to a prespecified boundary. However,...
Addition of Trabectedin to Doxorubicin in the First-Line Treatment of Advanced Leiomyosarcoma
In the French phase III LMS-04 trial reported in The Lancet Oncology, Pautier et al found that the addition of trabectedin to doxorubicin significantly prolonged progression-free survival as first-line treatment for patients with unresectable or metastatic leiomyosarcoma. Study Details In the...
Zanubrutinib vs Bendamustine/Rituximab in Previously Untreated Patients With CLL or SLL
As reported in The Lancet Oncology by Constantine S. Tam, MBBS, PhD, and colleagues, an interim analysis in the phase III SEQUOIA trial has shown significantly improved progression-free survival with first-line zanubrutinib vs bendamustine/rituximab in patients with chronic lymphocytic leukemia...
Addition of Brentuximab Vedotin to Chemotherapy in Patients With Stage III or IV Hodgkin Lymphoma: Overall Survival Analysis From ECHELON-1
As reported in The New England Journal of Medicine by Stephen M. Ansell, MD, PhD, and colleagues, an analysis at 6 years of follow-up in the phase III ECHELON-1 trial has shown significantly improved overall survival with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) vs ...
New Report Underscores Importance of Health Insurance Status and Cancer Stage at Diagnosis in Relation to Patient Survival
A new report published by Jingxuan Zhao, MPH, and colleagues in CA: A Cancer Journal for Clinicians showed that individuals without health insurance coverage were significantly more likely to be diagnosed with late-stage cancer and have worse survival rates after cancer diagnosis compared to...
Addition of Atezolizumab to Neoadjuvant Pertuzumab/Trastuzumab and Docetaxel in HER2-Positive Early Breast Cancer
In the Korean phase II Neo-PATH trial reported in JAMA Oncology, Ahn et al found that neoadjuvant treatment with atezolizumab, pertuzumab/trastuzumab, and docetaxel produced a pathologic complete response in 61% of patients with HER2-positive stage II/III breast cancer treated with the regimen....
LuPSMA Improves Progression-Free Survival vs Cabazitaxel in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) achieved longer progression-free survival with fewer toxicities compared with cabazitaxel in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer whose disease...
Study Reveals Cancer Screening Decreased Worldwide During Height of COVID-19 Pandemic
A study that surveyed cancer screening data included in medical journals worldwide from January 2020 into December 2021 showed significant decreases in the number of screenings for breast, colorectal, and cervical cancers during the early phase of the COVID-19 pandemic. The findings of the study,...
President Biden Appoints Cancer Panel Members, and Cancer Cabinet Unveils Priority Actions
On July 13, President Joe Biden announced his intent to appoint Mitchel Berger, MD; Carol Brown, MD; and Elizabeth M. Jaffee, MD, to the President’s Cancer Panel. The three are distinguished members of the scientific, research, and public health communities appointed by the President to advise him...
Responses to Teclistamab Reported in Early-Phase Trial of Highly Refractory Multiple Myeloma
In patients with multiple myeloma exposed or refractory to three standard therapies, treatment with the bispecific antibody teclistamab produced strong and durable responses in the phase I/II MajesTEC-1 study.1 The results of weekly subcutaneous dosing of teclistamab in 165 patients were presented...
Phase III Trial of Cabozantinib and Atezolizumab vs Sorafenib in Advanced Hepatocellular Carcinoma
As reported in The Lancet Oncology by Robin Kate Kelley, MD, and colleagues, the phase III COSMIC-312 trial has shown improved progression-free survival with cabozantinib plus atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma; interim analysis of overall survival showed...
Oncolytic Virus DNX-2401 for Newly Diagnosed Pediatric Patients With Diffuse Intrinsic Pontine Glioma
In a Spanish single-institution study reported in The New England Journal of Medicine, Pérez‑Larraya et al found that intratumoral infusion of the oncolytic adenovirus DNX-2401 followed by radiotherapy showed activity in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma...
First-Line Radiotherapy With or Without Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
As reported in the Journal of Clinical Oncology by Lassman et al, final survival reports from long-term follow-up of the phase III EORTC 26951 and RTOG 9402 studies show continued benefit of the addition of (neo)adjuvant procarbazine, lomustine, and vincristine to radiotherapy in patients with...
Outcomes in Pancreatic Cancer Surveillance Program for Carriers of Germline CDKN2A Pathogenic Variants
In a Dutch study reported in the Journal of Clinical Oncology, Klatte et al provided findings from a 20-year follow-up of a pancreatic cancer surveillance program including carriers of germline CDKN2A pathogenic variants. Study Details The study included 347 carriers in the Netherlands who...
Rucaparib Maintenance Improves Progression-Free Survival in Patients With Newly Diagnosed Advanced Ovarian Cancer Who Responded to Platinum-Based Therapy
Maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib led to a significant improvement in progression-free survival compared with placebo in patients with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based chemotherapy. The...
ARIEL4 Confirms Rucaparib’s Efficacy in Recurrent, BRCA-Mutated Ovarian Cancer: Does It Tell Us Anything New?
In March 2022, Kristeleit et al reported the results of the ARIEL4 trial1 of rucaparib in relapsed BRCA-mutant ovarian cancer in The Lancet Oncology (summarized in this issue of The ASCO Post) and are to be congratulated on this accomplishment. This report, along with the almost simultaneous...
